Fenstermaker Robert A, Ciesielski Michael J
Department of Neurosurgery, Roswell Park Cancer Institute and State University of New York School of Medicine and Biomedical Sciences, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Expert Rev Vaccines. 2014 Mar;13(3):377-85. doi: 10.1586/14760584.2014.881255.
There is growing interest in immunotherapy for malignant gliomas. This interest stems from a number of immunological observations, together with the failure of conventional therapeutic agents to produce broad and clinically meaningful improvements in survival and quality of life. The challenges faced in translating laboratory-based immunological observations to Phase I and II clinical trials for immunotherapy of gliomas are substantial. Nevertheless, as our understanding of the effects of active specific vaccination in glioma patients grows, results support optimism that such methods may eventually prove useful as an adjunctive treatment for these cancers. This paper highlights a number of barriers encountered in the translational development of a survivin-targeted peptide vaccine (SurVaxM) for patients with malignant gliomas.
免疫疗法治疗恶性胶质瘤正越来越受到关注。这种关注源于一些免疫学观察结果，以及传统治疗药物未能在生存和生活质量方面带来广泛且具有临床意义的改善。将基于实验室的免疫学观察结果转化为用于胶质瘤免疫治疗的I期和II期临床试验面临着巨大挑战。然而，随着我们对主动特异性疫苗接种对胶质瘤患者的影响的理解不断加深，结果支持了一种乐观的看法，即这种方法最终可能被证明对这些癌症的辅助治疗有用。本文重点介绍了针对恶性胶质瘤患者的survivin靶向肽疫苗（SurVaxM）在转化研究开发过程中遇到的一些障碍。
